ASpecial Meeting Review, 2013.Edition: Advances in the treatment of hepatitis C virus infection from EASL 2013,Gastroenterol Hepatol 9 1 -18
MorenoC,HezodeC,MarcellinP,BourgeoisS,FrancqueS,SamuelD, 2015.Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4,J Hepatol 62 1047 -55
ZeuzemS,DusheikoGM,SalupereR,MangiaA,FlisiakR,HylandRH, 2014.Sofosbuvir and ribavirin in HCV genotypes 2 and 3,N Engl J Med 370 1993 -2001
SulkowskiMS,Rodriguez-TorresM,LalezariJP, 2013.All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Presented at: 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD, -
AfdhalN,ReddyKR,NelsonDR, 2014.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection,N Engl J Med 370 1483 -93
AfdhalN,ZeuzemS,KwoP, 2014.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection,N Engl J Med 370 1889 -98
KowdleyKV,GordonSC,ReddyKR, 2014.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis,N Engl J Med 370 1879 -88
2014.Hepatitis C treatment gets into a new gear,J Coll Physicians Surg Pak 24 879 -81
BansalS,SingalAK,McGuireBM,AnandBS, 2015.Impact of all oral anti-hepatitis C virus therapy: A meta-analysis,World J Hepatol 7 806 -13
.December 2013, -
OsinusiA,MeissnerEG,LeeYJ,BonD,HeytensL,NelsonA, 2013.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial,JAMA 310 804 -11
ErmisF,TasciES, 2015.New treatment strategies for hepatitis C infection,World J Hepatol 7 2100 -09
De FranceschiL,FattovichG,TurriniF, 2000.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage,Hepatology 31 997 -1004
FarooqiJI,AlamA,AbbasZ,NaqviAB,ZuberiBF,NawazAA, 2016.Hep-net opinion about the management of patients with chronic hepatitis C in Pakistan in the era of available DAA,J Postgrad Med Inst 30 6 -14
Loustaud-RattiV,Debette-GratienM,JacquesJ,AlainS,MarquetP,SautereauD, 2016.Ribavirin: Past, present and future,World J Hepatol 8 123 -30
DrugAdministration, ., -
DrugAdministration, ., -
CadaDJ,Jasen CongCJ,DanialE., 2014.Formulary drug reviews Sofosbuvir,Baker Hosp Pharm 49 466 -78